• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Kindred Biosciences, Inc.

    4/1/21 4:57:44 PM ET
    $KIN
    Major Pharmaceuticals
    Health Care
    Get the next $KIN alert in real time by email
    SC 13G 1 p13g.htm SCHEDULE 13G
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.

    Securities and Exchange Commission, Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    (Amendment No._)*

    (Name of Issuer)

    Kindred Biosciences, Inc.

    (Title of Class of Securities)

    Common Stock, $0.0001 Par Value Per Share

    (CUSIP Number)

    494577109

    (Date of Event Which Requires Filing of this Statement)

    March 31, 2021

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:

    [  ] Rule 13d-1(b)

    [ x ] Rule 13d-1(c)

    [  ] Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).
    1


    CUSIP No. 494577109
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              3,850,200 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       3,850,200 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    3,850,200 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 8.7% (see Item 4)
     
    (12) Type of reporting person (see instructions)  PN
     

    2


    CUSIP No. 494577109
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              3,850,200 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       3,850,200 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    3,850,200 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 8.7% (see Item 4)
     
    (12) Type of reporting person (see instructions) CO
     

    3


    CUSIP No. 494577109
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              7,903 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       7,903 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    7,903 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1% (see Item 4)
     
    (12) Type of reporting person (see instructions) OO
     

    4


    CUSIP No. 494577109
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              3,858,103 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       3,858,103 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    3,858,103 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 8.7% (see Item 4)
     
    (12) Type of reporting person (see instructions)  IN
     

    5

    Item 1(a) Name of issuer:

    Kindred Biosciences, Inc.

    Item 1(b) Address of issuer's principal executive offices:

    1555 Bayshore Highway, Suite 200, Burlingame, California 94010

    2(a) Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, par value $0.0001 per
    share (“Shares”), of the Issuer held by certain investment funds it manages;
    (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with
    respect to Shares held by certain investment funds managed by Point72 Asset
    Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic
    Strategies”) with respect to Shares held by certain investment funds it
    manages; and (iv) Steven A. Cohen (“Mr. Cohen”) with respect to Shares
    beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc.
    and Cubist Systematic Strategies. Point72 Asset Management, Point72 Capital Advisors Inc.,
    Cubist Systematic Strategies, and Mr. Cohen have entered into a Joint
    Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1,
    pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the
    provisions of Rule 13d-1(k) of the Act.

    2(b) Address or principal business office or, if none, residence:

    The address of the principal business office of (i) Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road,
    Stamford, CT 06902; and (ii) Cubist Systematic Strategies is 55 Hudson Yards,
    New York, NY 10001.

    2(c) Citizenship:

    Point72 Asset Management is a Delaware limited partnership.
    Point72 Capital Advisors Inc. is a Delaware corporation.
    Cubist Systematic Strategies is a Delaware limited liability company.
    Mr. Cohen is a United States citizen.
    6

    2(d) Title of class of securities:

    Common Stock, $0.0001 Par Value Per Share

    2(e) CUSIP Number:

    494577109

    Item 3.

    Not applicable

    Item 4. Ownership

    As of the close of business on March 31, 2021:

    1. Point72 Asset Management, L.P.
    (a) Amount beneficially owned: 3,850,200
    (b) Percent of class: 8.7% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 3,850,200 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 3,850,200

    2. Point72 Capital Advisors, Inc.
    (a) Amount beneficially owned: 3,850,200
    (b) Percent of class: 8.7% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 3,850,200 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 3,850,200
    7

    3. Cubist Systematic Strategies, LLC
    (a) Amount beneficially owned: 7,903
    (b) Percent of class: <0.1% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 7,903 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 7,903

    4. Steven A. Cohen
    (a) Amount beneficially owned: 3,858,103
    (b) Percent of class: 8.7% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 3,858,103 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 3,858,103

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, and Mr. Cohen own directly no Shares. Pursuant to an investment
    management agreement, Point72 Asset Management maintains investment and
    voting power with respect to the securities held by certain investment funds it
    manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset
    Management. Pursuant to an investment management agreement, Cubist Systematic
    Strategies maintains investment and voting power with respect to the securities
    held by certain investment funds it manages. Mr. Cohen controls each of
    Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic
    Strategies. By reason of the provisions of Rule 13d-3 of the Securities Exchange
    Act of 1934, as amended, each of (i) Point72 Asset Management, Point72 Capital
    Advisors Inc., and Mr. Cohen may be deemed to beneficially own 3,850,200 Shares
     (constituting approximately 8.7% of the Shares outstanding) and (ii) Cubist Systematic
     Strategies and Mr. Cohen may be deemed to beneficially own 7,903 Shares
    (constituting <0.1% of the Shares outstanding). Each of Point72 Asset Management,
    Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen disclaims
    beneficial ownership of any of the securities covered by this statement.
    8

    Item 5. Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [  ].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.

    Not applicable

    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief,
    the securities referred to above were not acquired and are not held for the purpose
    of or with the effect of changing or influencing the control of the issuer of
    the securities and were not acquired and are not held in connection with or
    as a participant in any transaction having that purpose or effect, other than
    activities solely in connection with a nomination under§ 240.14a-11.
    9

    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.


    Dated: April 1, 2021


    POINT72 ASSET MANAGEMENT, L.P.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 CAPITAL ADVISORS, INC.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    CUBIST SYSTEMATIC STRATEGIES, LLC

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    STEVEN A. COHEN

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person
    Get the next $KIN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KIN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KIN
    Leadership Updates

    Live Leadership Updates

    See more
    • TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors

      TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors. Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops po

      10/24/22 9:00:00 AM ET
      $ELAN
      $PRTS
      $TSPQ
      $KIN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Auto & Home Supply Stores
      Consumer Discretionary
    • TCW Special Purpose Acquisition Corp. Announces Appointment of Nanxi Liu to Advisory Board

      TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to its Advisory Board, effective April 26, 2021. Ms. Liu is Co-Founder and CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, and was named one of Forbes 30 Under 30 and Fortune's 10 Most Promising Women Entrepreneurs. She also co-founded Nanoly Bioscience, a venture-backed biotech company that develops polymers that eliminate the need of refrigeration for vaccines and therapeutics. Ms. Liu serves on the Board of Directors of CarParts.com (NASDAQ:PRTS), a leading online provider of aut

      4/26/21 8:30:00 AM ET
      $PRTS
      $KIN
      Auto & Home Supply Stores
      Consumer Discretionary
      Major Pharmaceuticals
      Health Care

    $KIN
    SEC Filings

    See more
    • SEC Form 15-12B filed by Kindred Biosciences, Inc.

      15-12B - Kindred Biosciences, Inc. (0001561743) (Filer)

      9/7/21 6:09:47 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Kindred Biosciences, Inc.

      EFFECT - Kindred Biosciences, Inc. (0001561743) (Filer)

      9/2/21 12:15:28 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Kindred Biosciences, Inc.

      S-8 POS - Kindred Biosciences, Inc. (0001561743) (Filer)

      8/30/21 9:21:56 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care

    $KIN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors

      TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors. Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops po

      10/24/22 9:00:00 AM ET
      $ELAN
      $PRTS
      $TSPQ
      $KIN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Auto & Home Supply Stores
      Consumer Discretionary
    • Elanco Announces Agreement to Acquire Kindred Biosciences

      Bolt-on Acquisition Accelerates Elanco's Expansion in Pet Health Elanco to host conference call for investment community at 8:00 am Eastern Time    Elanco will acquire all outstanding stock of Kindred Biosciences at a price of $9.25 per share, or approximately $440 million, a premium of 52% based on the 30-day average. Transaction brings three potential blockbusters in the development phase, complements existing pipeline, and augments monoclonal antibody R&D capabilities. Increasing Investor Day revenue from innovation expectation by $100 million, to $600 million to $700 million by 2025, with significant opportunity beyond the period. Differentiated, disruptive portfolio in ato

      6/16/21 6:30:00 AM ET
      $KIN
      $ELAN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by Parvovirus

      SAN FRANCISCO, June 2, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030 in dogs infected by parvovirus. The primary endpoint was survival and the results showed 100% survival in the treated group versus 43% survival in the placebo group. KIND-030, a monoclonal antibody targeting canine parvovirus (CPV), is partnered with Elanco Animal Health (NYSE:ELAN). In this randomized, blinded, placebo-controlled study, KIND

      6/2/21 8:31:00 AM ET
      $KIN
      $ELAN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $KIN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kindred Biosciences downgraded by Lake Street with a new price target

      Lake Street downgraded Kindred Biosciences from Buy to Hold and set a new price target of $9.25 from $12.00 previously

      6/17/21 11:33:29 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • Kindred Biosciences downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Kindred Biosciences from Buy to Neutral and set a new price target of $9.25 from $9.00 previously

      6/17/21 6:07:16 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • Kindred Biosciences downgraded by Aegis Capital with a new price target

      Aegis Capital downgraded Kindred Biosciences from Buy to Hold and set a new price target of $9.25 from $16.00 previously

      6/16/21 9:21:39 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care

    $KIN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $KIN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 4 filed by Park West Asset Management Llc

      4 - Kindred Biosciences, Inc. (0001561743) (Issuer)

      9/13/21 4:30:38 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Chin Richard returned $15,884,757 worth of Common Stock to the company (1,717,271 units at $9.25), closing all direct ownership in the company

      4 - Kindred Biosciences, Inc. (0001561743) (Issuer)

      8/30/21 9:46:23 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Wee Wendy returned $727,170 worth of Common Stock to the company (78,613 units at $9.25), closing all direct ownership in the company

      4 - Kindred Biosciences, Inc. (0001561743) (Issuer)

      8/30/21 6:08:02 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Kindred Biosciences, Inc. (Amendment)

      SC 13G/A - Kindred Biosciences, Inc. (0001561743) (Subject)

      9/13/21 4:30:56 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Kindred Biosciences, Inc. (Amendment)

      SC 13D/A - Kindred Biosciences, Inc. (0001561743) (Subject)

      8/31/21 4:00:27 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Kindred Biosciences, Inc. (Amendment)

      SC 13D/A - Kindred Biosciences, Inc. (0001561743) (Subject)

      8/5/21 4:24:14 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care